Power determination during drug development: Is optimizing the sample size based on exposure-response analyses underutilized?

The use of model-based drug development (MBDD) has been demonstrated to improve the efficiency of clinical trial design. However, MBDD complexity can limit its use, particularly early in clinical development. In this tutorial a simple and generalizable exposure-response analysis approach to determine the power for dose ranging studies is presented and described. We identified situations where higher power and sample size reduction is achieved by utilizing the exposure-response powering methodology compared to conventional power calculations. This article is protected by copyright. All rights reserved.